Biosect, I think you misunderstand my position and we, as usual, are quite closely aligned. I did not think there would be an abstract, but nonetheless held out some degree of hope. In hindsight, that hope was silly and I will get to that in a moment. I do now believe a paper will be published soon. Due to past performance, I cannot say this is certain which is what they want the case to be in my mind.
Where we disagree is on the expectation setting. By purchasing the theater which is promotional, they have set an expectation that the Quiet Period has a finite ending and that is no later than June 4, 2022 at 3 pm. If they do not intend that to be the case, they owe us clarity by way of official communication setting different expectations as this is a reasonable assumption and game time is over regarding expectation setting.
Regarding the abstract. The theater occurs on the day that the scientific session opens. This is typically arrival day for most attendees and it is wise to have chosen the afternoon as the earlier session is unlikely to draw a crowd for this reason. Timing is perfect if anticipation has been built by a paper. They will be the buzz of ASCO after that talk. Since ASCO has a strict policy about not previewing data to be presented in the scientific session, and ASCO does not allow Encore data, they would likely frown on an abstract with new data alongside Encore data that was presented prior in a theater. Any new data other than primary, key secondary and safety data would prematurely expose other plans to release top line data. This is counterintuitive if one believes in the ‘catch them by surprise’ approach which I do. I also doubt a top tier journal would agree to that approach.
Therefore, they could not have their cake and eat it too. Either they get their publication soon or they could have had ASCO abstract but both was not possible (or perhaps that other high science meeting where LL is speaking remains a possibility.) And, the theater would have been useless on Day 1 if they went the ASCO scientific session route. So, when the theater was scheduled, I should have known with certainty that an abstract was ruled out. Hindsight is 20-20, and prescient is very difficult but not impossible.
Lets hope we are prescient about the publication timing, AND that I am prescient about their having received approval to premarket promote by FDA last August.
